Litifilimab sle. The main objective of the study is to learn about the effect The SLE Responder Index (SRI)–4 combined score was used to measure SLE disease activity across the entire body. The study will focus on participants who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. Jan 28, 2026 · About Litifilimab (BIIB059) Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting BDCA2 and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). In a phase 2 trial, Richard Furie and colleagues randomly assigned 132 participants with SLE to receive litifilimab 50 mg (n=6), 150 mg (n=6), or 450 mg (n=64), or placebo (n=56) subcutaneously at weeks 0, 2, 4, 8, 12, 16, and 20 Phase 2 Trial of Litifilimab for SLE Shows Some Promise Systemic lupus erythematosus (SLE), is an autoimmune disease that is characterized by higher levels of an immune system molecule known as interferon (IFN). Normally, IFN helps activate the immune system in cases of infection, but in those with autoimmunity, it may exacerbate disease Jul 28, 2022 · About Litifilimab (BIIB059) Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Sep 7, 2022 · The trial design was subsequently modified; adults with SLE, arthritis, and active skin disease were randomly assigned to receive either litifilimab at a dose of 450 mg or placebo. 4 days ago · About Litifilimab (BIIB059) Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting BDCA2 and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Litifilimab, a humanised monoclonal antibody against blood dendritic cell antigen 2 (BDCA2), might be an effective treatment for systemic lupus erythematosus (SLE). In a phase 2 trial involving participants with cutaneous lupus erythematosus, treatment with litifilimab was superior to placebo with regard to a measure of skin disease activity over a period of . Litifilimab, also known as BIIB059, is a humanized IgG1 monoclonal antibody (mAb) targeting BDCA2 and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). 2 days ago · Biogen’s lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in two forms of the autoimmune Feb 10, 2026 · In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The results demonstrated that, on average, participants who received litifilimab had a lower total number of swollen and tender joints after 24 weeks than those who received placebo. otgzbt geckk uvvyga wnmy dyhjlcp